TY - JOUR
T1 - Utility of the plasma pancreatic polypeptide response to modified sham feeding in diabetic gastroenteropathy and non-ulcer dyspepsia
AU - Desai, Anshuman
AU - Low, Phillip A.
AU - Camilleri, Michael
AU - Singer, Wolfgang
AU - Burton, Duane
AU - Chakraborty, Subhankar
AU - Bharucha, Adil E.
N1 - Funding Information:
Funding information This work is made possible by NIH RO1 DK068055 to Dr Bharucha and CTSA Grant Number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH.
Publisher Copyright:
© 2019 John Wiley & Sons Ltd
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Background: The relationship between cardiovascular and gastrointestinal (ie, plasma pancreatic polypeptide [PP] response to modified sham feeding [MSF]) indices of vagal function is unclear. Hyperglycemia inhibits PP secretion via vagally mediated mechanisms. Our aims were to (a) compare the PP response, (b) its relationship with glycemia, and (c) the relationship between PP response to MSF, gastric emptying (GE) of solids, and symptoms during GE study in healthy controls, patients with diabetic gastroenteropathy (DM), and non-ulcer dyspepsia (NUD). Methods: In 24 healthy controls, 40 DM, and 40 NUD patients, we measured plasma PP concentrations during MSF, cardiovagal functions, GE, and symptoms during a GE study. Key Results: Baseline PP concentrations were higher in DM than in controls and NUD (P =.01), and in type 2 than in type 1 DM patients (P <.01). The PP increment during MSF was normal (≥20 pg/mL) in 70% of controls, 54% of DM, and 47% of NUD patients. Overall, the PP response and cardiovagal tests were concordant (P =.01). Among patients with a reduced PP increment with MSF, 7/10 of T1DM and 1/7 of T2DM patients had moderate or severe cardiovagal dysfunctions (P <.05). The PP response to MSF was not associated with GE. Conclusions & Inferences: Up to 30% of healthy controls have a reduced PP increment during MSF, limiting the utility of this test to detect vagal injury. The PP response is more useful when it is normal than abnormal. A reduced PP response is more likely to be associated with cardiovagal dysfunctions in T1DM than in T2DM.
AB - Background: The relationship between cardiovascular and gastrointestinal (ie, plasma pancreatic polypeptide [PP] response to modified sham feeding [MSF]) indices of vagal function is unclear. Hyperglycemia inhibits PP secretion via vagally mediated mechanisms. Our aims were to (a) compare the PP response, (b) its relationship with glycemia, and (c) the relationship between PP response to MSF, gastric emptying (GE) of solids, and symptoms during GE study in healthy controls, patients with diabetic gastroenteropathy (DM), and non-ulcer dyspepsia (NUD). Methods: In 24 healthy controls, 40 DM, and 40 NUD patients, we measured plasma PP concentrations during MSF, cardiovagal functions, GE, and symptoms during a GE study. Key Results: Baseline PP concentrations were higher in DM than in controls and NUD (P =.01), and in type 2 than in type 1 DM patients (P <.01). The PP increment during MSF was normal (≥20 pg/mL) in 70% of controls, 54% of DM, and 47% of NUD patients. Overall, the PP response and cardiovagal tests were concordant (P =.01). Among patients with a reduced PP increment with MSF, 7/10 of T1DM and 1/7 of T2DM patients had moderate or severe cardiovagal dysfunctions (P <.05). The PP response to MSF was not associated with GE. Conclusions & Inferences: Up to 30% of healthy controls have a reduced PP increment during MSF, limiting the utility of this test to detect vagal injury. The PP response is more useful when it is normal than abnormal. A reduced PP response is more likely to be associated with cardiovagal dysfunctions in T1DM than in T2DM.
KW - autonomic
KW - autonomic neuropathy
KW - diabetes mellitus
KW - diabetic gastroparesis
KW - vagus
UR - http://www.scopus.com/inward/record.url?scp=85074651992&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074651992&partnerID=8YFLogxK
U2 - 10.1111/nmo.13744
DO - 10.1111/nmo.13744
M3 - Article
C2 - 31642143
AN - SCOPUS:85074651992
SN - 1350-1925
VL - 32
JO - Neurogastroenterology and Motility
JF - Neurogastroenterology and Motility
IS - 2
M1 - e13744
ER -